Immunochemotherapy with interferon-γ and multidrug therapy for multibacillary leprosy

Acta Tropica

Volumn 72, Issue 2, 1999, Pages 185-201

  Barral Netto, M ^a,b   Santos, S ^a   Santos, I ^a   Von Sohsten, R ^a   Bittencourt, A L ^a   Carvalho, E M ^a   Barral, A ^a   Waters, M ^c  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b LIMI   (Brazil)

^c HOSPITAL FOR TROPICAL DISEASES   (United Kingdom)

Author keywords

Immunochemotherapy; Interferon ; Leprosy; Multi drug therapy; Multibacillary leprosy

Indexed keywords

CLOFAZIMINE; DAPSONE; GAMMA INTERFERON; IMMUNOGLOBULIN M ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; MARKER; NEOPTERIN; PHYTOHEMAGGLUTININ; RECOMBINANT GAMMA INTERFERON; RIFAMPICIN;

DRUG PRESCRIBING; HEALTH CARE; LEPROSY;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LEPROSY; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHILD; CLOFAZIMINE; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-GAMMA, RECOMBINANT; LEPROSTATIC AGENTS; LEPROSY; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPTERIN; RIFAMPIN; SKIN;

MYCOBACTERIUM LEPRAE;

EID: 0033015737     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(98)00097-7     Document Type: Article

References (38)

1. Ayehunie S., Sonnerborg A., Yemane-Berhan T., Zewdie D.W., Britton S., Strannegard O. Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin. Exp. Immunol. 91:1993;37-42.
2. Barral-Netto M., Barral A., Santos S., Carvalho E.M., Badaro R., Rocha H., Reed S.G., Johnson W.D. Jr. Soluble interleukin-2 receptor as an agent of serum mediated suppression in human visceral leishmaniasis. J. Immunol. 147:1991;281-284.
3. Beckham J.C., Caldwell D.S., Peterson B.L., Pippen A.M.M., Currie M.S., Keefe F.J., Weinberg J.B. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-a, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J. Clin. Immunol. 12:1992;353-361.
4. Botasso O., Besuschio S., Merlin V., Morini J.C., Bernabo J., Falcoff R., Falcoff E. Lepromatous leprosy treated with recombinant IFN-gamma: cutaneous histologic changes. Int. J. Dermatol. 31:1992;813-817.
5. Brown A.E., Webster H.K., Teja-Isavadharm P., Keeratithakul D. Macrophage activation in falciparum malaria as measured by neopterin interferon-gamma. Clin. Exp. Immunol. 82:1990;97-101.
6. Cush J.J., Rothlein R., Lindsley H.B., Mainolfi E.A., Lipsky P.E. Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum. 36:1993;1098-1102.
7. Damasco M.H.S., Sarno E.N., Lobao A.S., Alvarenga F.B.F., Porto J.A., Rosankaimer F., Kaplan G. Effect of cutaneous cell-mediated immune response to rIFN-gamma on Mycobacterium leprae viability in the lesions of lepromatous leprosy. Braz. J. Med. Biol. Res. 25:1992;457-465.
8. Dustin M.L., Rothlein R., Bhan A.K., Dinarello C.A., Springer T.A. Induction by IL-1 and IFN-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J. Immunol. 137:1986;245-254.
9. Fuchs D., Möller A.A., Reibnegger G., Werner E.R., Werner-Felmayer G., Dierich M.P., Wachter H. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol. Lett. 28:1991;207-212.
10. Fuchs D., Weiss G., Reibnegger G., Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit. Rev. Clin. Lab. Sci. 29:1992;307-341.
11. Hancock G.E., Cohn Z.A., Kaplan G. The generation of antigen-specific, major histocompatibility complex-restricted cytotoxic T lymphocytes of the CD4+ phenotype: enhancement by the cutaneous administration of interleukin-2. J. Exp. Med. 169:1989;909-919.
12. Henderson D.C., Sheldon J., Riches P., Hobbs J.R. Cytokine induction of neopterin production. Clin. Exp. Immunol. 83:1991;479-482.
13. Ho A.D., Grossman M., Knauf W. et al. Plasma levels of soluble CD8 antigen and IL-2 receptor antigen in patients with hairy cell leukemia, relationship with splenectomy and with clinical response to therapy. Leukemia. 3:1989;718-723.
14. Kaplan G., Weinstein D.E., Steinman R.M., Levis W.R., Elvers U., Patarroyo M.E., Cohn Z.A. An analysis of in vitro T cell responsiveness in lepromatous leprosy. J. Exp. Med. 162:1985;917-929.
15. Kaplan G., Mathur N.K., Job C.K., Nath I., Cohn Z.A. Effect of multiple IFN-gamma injections on the disposal of Mycobacterium leprae. Proc. Natl. Acad. Sci. USA. 86:1989;8073-8077.
16. Landmann R., Ludwig C., Wesp M. et al. Prolonged interferon-gamma application by subcutaneous infusion in cancer patients: differential response of serum CD14, neopterin, and monocyte HLA class I and II antigens. J. Interferon Res. 12:1992;103-111.
17. Libraty D.H., Airan L.E., Uyemura K., Jullien D., Spellberg B., Rea T.H., Modlin R.L. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. J. Clin. Invest. 99:1997;336-341.
18. Magalini S.C., Nanni G., Agnes S., Avolio A.W., Salvatori M., Manna R., Castagneto M. Neopterin, amyloid A, C-reactive protein, gamma-interferon, and interleukin-2 receptor in diagnosis of posttransplantation rejection. Transplant. Proc. 23:1991;2267-2268.
19. Nathan C.F., Murray H.W., Wiebe M.E., Rubin B.Y. Identification of interferon gamma as the lymphokine that activates human macrophages oxidative metabolism and antimicrobial activity. J. Exp. Med. 158:1983;670-689.
20. Nathan C.F., Kaplan G., Lewis W.R. et al. Local and systemic effects of low doses of recombinant interferon after intradermal injection in patients with lepromatous leprosy. N. Engl. J. Med. 315:1986;6.
21. Nathan C.F., Squires K., Griffo W. et al. Widespread intradermal accumulation of mononuclear leukocytes in lepromatous leprosy patients treated systemically with recombinant interferon gamma. J. Exp. Med. 172:1990;1509-1512.
22. Pui C., Schell M.J., Vodian M.A., Kline S., Mirro J., Crist W.M., Behm F.G. Serum CD4, CD8, and interleukin-2 receptor levels in childhood acute myeloid leukemia. Leukemia. 5:1991;249-254.
23. Pui C., Ip S., Thompson E. et al. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood. 73:1989;209-213.
24. Ridley D.S., Jopling W.H. Classification of leprosy according to immunity. Int. J. Lepr. Other Mycobact. Dis. 34:1966;255-273.
25. Rieckmann P., Scholze G., Weichselbraum I., Ganapati R., Prange H.W. Soluble adhesion molecules in sera of patients with leprosy: levels of soluble intercellular adhesion molecule-1 (sICAM-1) rapidly decrease during multi-drug therapy. Clin. Exp. Immunol. 105:1996;65-68.
26. Rothlein R., Mainolfi E.A., Czajkowski M., Marlin S.D. A form of circulating ICAM-1 in human serum. J. Immunol. 147:1991;3788-3793.
27. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boufin B., Yarchoan R., Nelson D.L. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 135:1985;3172-3177.
28. Rubin L.A., Nelson D.L. The soluble IL-2 receptor: biology, function, and clinical applications. Ann. Intern. Med. 113:1990;619-627.
29. Sampaio E.P., Moreira A.L., Sarno E.N., Malta A.M., Kaplan G. Prolonged treatment with recombinant IFN-gamma induces Erythema Nodosum Leprosum. J. Exp. Med. 175:1992;1729-1737.
30. Sampaio E.P., Malta A.M., Sarno E.N., Kaplan G. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 64:1996;268-273.
31. Schriefer A., Barral A., Carvalho E.M., Barral-Netto M. Serum soluble markers in the evaluation of treatment in human visceral leishmaniasis. Clin. Exp. Immunol. 102:1995;535-540.
32. Seth R., Raymond F.D., Makgoba M.W. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet. 338:1991;83-84.
33. Sfikakis P.P., Tesar J., Baraf H., Lipnick R., Klipple G., Tsokos G.C. Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin. Immunol. Immunopathol. 68:1993;88-92.
34. SivaSai K.S.R., Prasad H.K., Misra R.S., Ramesh V., Wilfred D., Nath I. Effect of recombinant interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. Int. J. Lepr. Other Mycobact. Dis. 61:1993;259-269.
35. Springer T.A. The sensation and regulation of interactions with the extracellular environment: the cell biology of lymphocyte adhesion receptors. Annu. Rev. Cell Biol. 6:1990;359-402.
36. Tilz G.P., Zangerle R., Weiss G., Fritsch P., Wachter H., Fuchs D. Association between serum-soluble CD8 levels and parameters of immune activation in patients with human immunodeficiency virus infection. Klin. Wochenschr. 70:1992;662-664.
37. Yamamura M., Uyemura K., Deans R.J., Weinberg K., Rea T.H., Bloom B.R., Modlin R.L. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 254:1991;277-279.
38. Zerlotti H., Grotto W., Costa F.F., Carnéiro M.V., Neto G.C.G. Serum neopterin in patients with Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 88:1994;75.